BUSINESSJun 2 · 17:00 UTCSTAT NEWSAllison DeAngelis

STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial

Longevity startup NewLimit raised $435 million in a Series C funding round led by Founders Fund, Thrive Capital, Lilly Ventures, and tech entrepreneurs Nat Friedman and Daniel Gross. The company, founded in 2021 by Brian Armstrong, Blake Byers, and Jacob Kimmel, plans to launch its first clinical trial of a liver medicine and is now valued at $3.1 billion.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

NewLimitorganizationFounders FundorganizationThrive CapitalorganizationLilly VenturesorganizationBrian ArmstrongpersonBlake ByerspersonJacob KimmelpersonNat FriedmanpersonDaniel Grossperson

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHMay 22 · 11:00 UTC
STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion
HEALTHMay 14 · 11:00 UTC
STAT+: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
TECHNOLOGYMay 12 · 16:17 UTC
Google AI legend raises big money for startup targeting this cutting-edge goal
BUSINESSMay 6 · 20:39 UTC
Insurance startup Corgi hits $1.3B valuation 4 months after its Series A
BUSINESSApr 27 · 11:25 UTC
Novo-Backed Biotech Hemab Seeks to Raise $212 Million in US IPO
BUSINESSApr 27 · 14:26 UTC
Sequoia and Nvidia Back Ex-DeepMind Researcher’s New AI Startup at $5.1 Billion Value